JCR Pharmaceuticals Second Quarter 2025 Earnings: Misses Expectations

JCR Pharmaceuticals (TSE:4552) Second Quarter 2025 Results

Key Financial Results

• Revenue: JP¥8.51b (down 37% from 2Q 2024).
• Net loss: JP¥892.0m (down by 125% from JP¥3.64b profit in 2Q 2024).
• JP¥7.12 loss per share (down from JP¥29.19 profit in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

JCR Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 25%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 4.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - JCR Pharmaceuticals has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.